Coutinho Thais, Lamai Olabimpe, Nerenberg Kara
Canadian Women's Heart Health Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada.
Division of Cardiac Prevention & Rehabilitation, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Curr Treat Options Cardiovasc Med. 2018 Jun 19;20(7):56. doi: 10.1007/s11936-018-0653-8.
Cardiovascular diseases (CVDs) are the principal killers of women. In this review, we summarize data regarding CVD and mortality after hypertensive disorders of pregnancy (HDP), and highlight clinical, research and policy needs to mitigate this risk.
Robust data indicate that women with HDP have substantially higher risk of future CVD, with a 3.7-fold increase in the risk of chronic hypertension, a 4.2-fold increase in the risk of heart failure, an 81% increase in the risk of stroke, and double the risk of atrial arrhythmias, coronary heart disease, and mortality when compared to women with normotensive pregnancies. Potential explanations include (1) the effect of pregnancy as a "stress test" in women destined to develop CVD, (2) mediation by conventional risk factors, (3) long-term vascular damage sustained during the preeclamptic episode, and (4) preexisting abnormalities in arterial health predisposing women to HDP, and, subsequently, CVD. Women with HDP have significantly increased risk of CVD and mortality. Risk scores including obstetric history are necessary to better estimate a woman's cardiovascular risk. In addition, comprehensive policies promoting systematic risk assessment and modification after HDP are critically needed to improve health, wellness, and survival of affected women.
心血管疾病(CVDs)是女性的主要死因。在本综述中,我们总结了关于妊娠高血压疾病(HDP)后心血管疾病和死亡率的数据,并强调了降低这种风险的临床、研究和政策需求。
有力数据表明,患有HDP的女性未来患心血管疾病的风险显著更高,与血压正常的孕妇相比,患慢性高血压的风险增加3.7倍,患心力衰竭的风险增加4.2倍,患中风的风险增加81%,患房性心律失常、冠心病和死亡的风险增加一倍。潜在的解释包括:(1)妊娠作为对注定要患心血管疾病的女性的“压力测试”的影响;(2)传统风险因素的介导作用;(3)子痫前期发作期间长期的血管损伤;(4)动脉健康方面预先存在的异常使女性易患HDP,进而易患心血管疾病。患有HDP的女性患心血管疾病和死亡的风险显著增加。包括产科病史在内的风险评分对于更好地评估女性的心血管风险是必要的。此外,迫切需要全面的政策来促进HDP后系统的风险评估和干预,以改善受影响女性的健康、福祉和生存率。